By using a composite behavioral and circuit biomarker to identify a subgroup of patients with depression and targeting the α2A receptor with GIR, we demonstrate for the first improvements in neural circuit function, clinical outcomes, cognitive performance, and psychosocial outcomes. The gene discussed is GPR83; the disease is depressive symptom measurement.